Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Castle Biosciences, Inc.
< Previous
1
2
3
4
Next >
Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting
May 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
May 24, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC
May 19, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings
May 10, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Reports First Quarter 2022 Results
May 09, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety
May 06, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives
May 03, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests
April 29, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for TissueCypher® Barrett’s Esophagus Test and Ability to Identify Patients at High Risk of Progressing to Esophageal Cancer
April 27, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Completes Acquisition of AltheaDx
April 26, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9
April 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Untested Patients
April 21, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress
April 20, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference
April 18, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Acquire AltheaDx
April 04, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)
March 29, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making
March 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
February 14, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 07, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
February 03, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award
February 02, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022
January 24, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors
January 13, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma
January 12, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results
January 10, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present at the 24th Annual Needham Growth Conference
December 28, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Completes Acquisition of Cernostics
December 06, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio
November 24, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology
November 19, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit